Security
Biomea Fusion, Inc. Common Stock · BMEA
BMEANASDAQCommon stockCurrentCIK 1840439Updated Nov 12, 2026
BMEA price & chart
Loading TradingView…
NASDAQ:BMEA on TradingView ↗About the company
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapeutic candidates, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
In the news
Biomea Fusion Announces Proposed Public Offering of Securities ↗
Seeking Alpha
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow ↗
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript ↗
Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure ↗
Recent filings
10-Q filing
Financial Statements and Exhibits
Items 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
424B5 filing
Other Events
Items 8.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 55,187,000Source | 110,419,000Source | 36,873,000Source | 73,163,000Source | 136,164,000Source | 46,385,000Source | 55,055,000Source | 168,494,000Source | 58,572,000Source | 79,938,000Source | 199,927,000Source | 129,307,000Source |
| Property, Plant and Equipment, NetUSD | 200,000Source | 4,228,000Source | 47,000Source | 2,831,000Source | 4,445,000Source | 67,000Source | 3,298,000Source | 4,806,000Source | 153,000Source | 3,766,000Source | 5,159,000Source | 5,841,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 46,642,000Source | 87,952,000Source | 34,824,000Source | 56,224,000Source | 113,286,000Source | 44,693,000Source | 35,864,000Source | 144,918,000Source | 55,812,000Source | 58,279,000Source | 176,866,000Source | 111,899,000Source |
| Assets, CurrentUSD | 49,440,000Source | 93,598,000Source | 36,428,000Source | 64,663,000Source | 116,288,000Source | 46,318,000Source | 44,685,000Source | 147,566,000Source | 58,050,000Source | 68,332,000Source | 179,181,000Source | 117,819,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,798,000Source | 5,646,000Source | 1,235,000Source | 8,439,000Source | 3,002,000Source | 1,256,000Source | 8,821,000Source | 2,648,000Source | 2,238,000Source | 10,053,000Source | 2,315,000Source | 4,770,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,178,000Source | 7,595,000Source | — | 5,296,000Source | 8,315,000Source | — | 6,086,000Source | 9,013,000Source | 0Source | 6,852,000Source | 9,714,000Source | 2,151,000Source |
| Other Assets, NoncurrentUSD | 0Source | 4,629,000Source | 398,000Source | 4,000Source | 6,747,000Source | — | 617,000Source | 6,740,000Source | 0Source | 619,000Source | 5,503,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 39,568,000Source | 34,447,000Source | 24,736,000Source | 45,653,000Source | 32,216,000Source | 27,666,000Source | 26,318,000Source | 33,180,000Source | 29,020,000Source | 28,365,000Source | 30,690,000Source | 20,768,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 4,000Source | 7,000Source | 6,000Source | 4,000Source | 7,000Source | 4,000Source | 4,000Source | 7,000Source | 4,000Source | 4,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 469,273,000Source | 433,917,000Source | 481,921,000Source | 464,757,000Source | 429,106,000Source | 480,175,000Source | 445,246,000Source | 423,196,000Source | 478,593,000Source | 438,820,000Source | 418,058,000Source | 240,107,000Source |
| Retained Earnings (Accumulated Deficit)USD | -453,660,000Source | -357,949,000Source | -469,791,000Source | -437,253,000Source | -325,162,000Source | -461,463,000Source | -416,513,000Source | -287,886,000Source | -449,048,000Source | -387,251,000Source | -248,825,000Source | -131,570,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -1,000Source |
| Stockholders' Equity Attributable to ParentUSD | 15,619,000Source | 75,972,000Source | 12,137,000Source | 27,510,000Source | 103,948,000Source | 18,719,000Source | 28,737,000Source | 135,314,000Source | 29,552,000Source | 51,573,000Source | 169,237,000Source | 108,539,000Source |
| Liabilities and EquityUSD | 55,187,000Source | 110,419,000Source | 36,873,000Source | 73,163,000Source | 136,164,000Source | 46,385,000Source | 55,055,000Source | 168,494,000Source | 58,572,000Source | 79,938,000Source | 199,927,000Source | 129,307,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 15,565,000Source | 27,572,000Source | 10,483,000Source | 17,568,000Source | 25,163,000Source | 9,294,000Source | 19,817,000Source | 25,254,000Source | 11,101,000Source | 21,673,000Source | 22,860,000Source | 19,101,000Source |
| Operating Lease, Liability, CurrentUSD | 787,000Source | 2,692,000Source | 877,000Source | 755,000Source | 3,289,000Source | 1,239,000Source | 1,426,000Source | 3,166,000Source | 1,461,000Source | 2,079,000Source | 2,466,000Source | 618,000Source |
| Accounts Payable, CurrentUSD | 6,397,000Source | 8,987,000Source | 3,306,000Source | 8,378,000Source | 5,828,000Source | 4,613,000Source | 7,707,000Source | 4,709,000Source | 3,233,000Source | 12,932,000Source | 6,851,000Source | 6,826,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,089,000Source | 6,875,000Source | 0Source | 6,299,000Source | 7,053,000Source | 0Source | 6,501,000Source | 7,926,000Source | 128,000Source | 6,692,000Source | 7,830,000Source | 1,667,000Source |
| Additional Financial Items | ||||||||||||
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 1,150,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -12,415,000Source | -29,262,000Source | -61,797,000Source | -138,426,000Source | -117,255,000Source | -81,828,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,582,000Source | 3,169,000Source | 9,520,000Source | 19,094,000Source | 14,131,000Source | 10,336,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,380,000Source | -5,220,000Source | -9,700,000Source | 6,088,000Source | 2,562,000Source | 2,960,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -11,669,000Source | -25,667,000Source | -70,371,000Source | -119,894,000Source | -96,592,000Source | -62,417,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 550,000Source | 0Source | — | -362,000Source | -2,220,000Source | 27,341,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | — | 362,000Source | 3,370,000Source | 1,030,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 3,252,000Source | 67,904,000Source | 1,668,000Source | 163,798,000Source | 1,239,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -11,119,000Source | -22,415,000Source | -2,467,000Source | -118,588,000Source | 64,986,000Source | -33,837,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 47,011,000Source | 88,321,000Source | 35,193,000Source | 56,593,000Source | 45,062,000Source | 36,233,000Source | 56,181,000Source | 58,648,000Source | 177,236,000Source | 112,250,000Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | 400,000Source | 400,000Source | — | 500,000Source | 46,000Source | 468,000Source | 1,409,000Source | 1,748,000Source | 1,515,000Source | 691,000Source |
| Dividends PayableUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 4,199,000Source | 6,795,000Source | 3,624,000Source | 4,710,000Source | 3,654,000Source | 6,815,000Source | 19,328,000Source | 25,985,000Source | 23,589,000Source | 20,921,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,407,000Source | -32,787,000Source | -8,328,000Source | -20,740,000Source | -12,415,000Source | -29,262,000Source | -61,797,000Source | -138,426,000Source | -117,255,000Source | -81,828,000Source |
| Operating ExpensesUSD | — | — | 20,805,000Source | 34,039,000Source | 12,766,000Source | 21,276,000Source | 12,774,000Source | 29,712,000Source | 83,512,000Source | 144,070,000Source | 126,135,000Source | 83,634,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 3,257,000Source | 4,908,000Source | — | 161,803,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -20,805,000Source | -34,039,000Source | -12,766,000Source | -21,276,000Source | -12,774,000Source | -29,712,000Source | -83,512,000Source | -144,070,000Source | -126,135,000Source | -83,634,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,407,000Source | -32,787,000Source | -8,328,000Source | -20,740,000Source | -12,415,000Source | -29,262,000Source | -61,797,000Source | -138,426,000Source | -117,255,000Source | -81,828,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.27Source | -0.91Source | -0.12Source | -0.51Source | -0.17Source | -0.8Source | -1.18Source | -3.83Source | -3.44Source | -2.8Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.27Source | -0.91Source | -0.12Source | -0.51Source | -0.17Source | -0.8Source | -1.18Source | -3.83Source | -3.44Source | -2.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 59,848,325Source | 36,220,736Source | 72,360,235Source | 40,630,403Source | 72,299,440Source | 36,627,148Source | 52,228,068Source | 36,105,671Source | 34,106,923Source | 29,271,777Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 59,848,325Source | 36,220,736Source | 72,360,235Source | 40,630,403Source | 72,299,440Source | 36,627,148Source | 52,228,068Source | 36,105,671Source | 34,106,923Source | 29,271,777Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,199,000Source | 6,795,000Source | 3,624,000Source | 4,710,000Source | 3,654,000Source | 6,815,000Source | 19,328,000Source | 25,985,000Source | 23,589,000Source | 20,921,000Source |
| Interest and Other IncomeUSD | — | — | 4,398,000Source | 1,252,000Source | 319,000Source | 309,000Source | 430,000Source | 450,000Source | 1,858,000Source | 5,644,000Source | 8,880,000Source | 1,806,000Source |
| Interest Income (Expense), NetUSD | — | — | 4,398,000Source | 1,252,000Source | 319,000Source | 309,000Source | 430,000Source | 450,000Source | 1,858,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 20,805,000Source | 34,039,000Source | 12,766,000Source | 21,276,000Source | 12,774,000Source | 29,712,000Source | 83,512,000Source | 144,070,000Source | 126,135,000Source | 83,634,000Source |
| Research and Development ExpenseUSD | — | — | 14,401,000Source | 27,244,000Source | 9,142,000Source | 16,566,000Source | 9,120,000Source | 22,897,000Source | 61,979,000Source | 118,085,000Source | 102,546,000Source | 62,713,000Source |
Filing attachments
bmea-ex99_1.htm · 8-K · 2026-11-10
Exhibit 99.1 Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights • Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 • Enrollment ongoing in the Phase II COVALENT-212 clinical trial evaluating icovamenib in patients with T2D not achieving glycemic targets on GLP-1 receptor agonist (“GLP-1 RA”)-based therapy; topline…
Read attachment ↗d158362dex991.htm · 8-K · 2026-10-14
Exhibit 99.1 GLP-131 Phase 1 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026 Legal Disclaimer & Forward-looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risks, uncertainties, and other factors…
Read attachment ↗d158362dex992.htm · 8-K · 2026-10-14
Exhibit 99.2 Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo. No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations among all BMF-650-treated MAD participants. A rapid one-step titration to the target dose of 400 mg QD in Cohort 5 was equa…
Read attachment ↗bmea-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 bmea-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes ("T2D"); data expected in the first quarter of 2027 • Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists ("GLP…
Read attachment ↗bmea-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 bmea-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights • Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12‑week clinical dosing that has been used to date • Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes (“T1D”), supporting proposed mechanism of ac…
Read attachment ↗d142809dex991.htm · 8-K · 2026-04-28
EX-99.1 2 d142809dex991.htm EX-99.1 EX-99.1 COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 Diabetes Exhibit 99.1 Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risks, uncertainties, and other factors that may cause the actual …
Read attachment ↗